ID-5184 Wonca Abstracts supplement A-K 13-10-23 - Flipbook - Page 231
WONCA 2023 Supplement 1: WONCA 2023 abstracts (A–K)
A
B
Roadmap to liver cancer control in Australia
C
Eleonora Feletto1, Amanda McAtmaney4, Prof Jacob George2, Dr Nicole Allard3,
Ms Claire Latumahina1, Megan Varlow4, Karen Canfell1, Paul Grogan1
D
1
The Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW,
Storr Liver Centre, The Westmead Institute for Medical Research Storr Liver Centre, Westmead
Hospital and University of Sydney, 3The Doherty Institute, 4Cancer Council Australia
2
E
F
G
H
I
J
K
Liver cancer incidence and mortality rates are rapidly rising in Australia and projected to continue
increasing over the next 20 years. The current five-year survival rate is 22.0% (2014–18). Hepatocellular
carcinoma (HCC) is the most common type and its major risk factors include infections (hepatitis B,
hepatitis C, liver flukes in endemic areas), behavioural factors (alcohol, tobacco), metabolic factors
(excess adiposity) and aflatoxins. There is promising evidence to support prevention and early
detection activities that start from infant hepatitis B vaccination to early detection interventions, which
all contribute to improving liver cancer outcomes.
In 2019, a Roadmap to Liver Cancer Control in Australia project was established to identify key priority
areas and strategies for collective action, and to set a shared agenda to drive improvements in liver
outcomes.
This presentation will provide an overview of the four stages that informed the Roadmap development,
including:
•
•
•
•
a scoping review of screening for advanced liver disease and HCC surveillance
an environmental scan of current HCC care service delivery models
consultations with key stakeholders, including an expert roundtable
the development of clinical practice guidelines for HCC surveillance for people at high risk.
We will share an outline of the final Roadmap, launching in 2023, with five-, 10- and 20-year actions.
Future strategies prioritise efforts in hepatitis B vaccination (from infancy), screening and treatment for
hepatitis B and C, prevention of risk factors and surveillance, which are critical later in the life course.
The Roadmap clearly highlights the need to engage with Australians at high risk, policy makers and
clinicians to improve health literacy, awareness, understanding and utilisation of liver cancer control
activities across the life course to achieve better outcomes.
229